ASND - アセンディス・ファ―マ (Ascendis Pharma A/S) アセンディス・ファ―マ

 ASNDのチャート


 ASNDの企業情報

symbol ASND
会社名 Ascendis Pharma A/S (アセンディス・ファ―マ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 Ascendis Pharma A/S is a clinical-stage biopharmaceutical company. The Company is engaged in applying its TransCon technology to develop sustained release prodrug therapies with several product candidates in clinical and preclinical development. The Company is developing its product candidate TransCon human growth hormone (TransCon hGH) for once-weekly administration to treat growth hormone deficiency (GHD) and other indications. In addition to TransCon hGH the Company has developed a pipeline of long-acting prodrug product candidates such as TransCon Treprostinil for the treatment of pulmonary arterial hypertension (PAH) TransCon Peptides for the treatment of diabetes and TransCon Ranibizumab for the treatment of ophthalmology. It is also using its TransCon technology platform to develop TransCon Parathyroid Hormone (TransCon PTH) for hypoparathyroidism a rare endocrine disorder of calcium and phosphate metabolism.   アセンディス・ファ―マは、デンマ―クのバイオ医薬品会社。高価値の薬のプロドラッグ・バ―ジョンを開発。小児成長ホルモン欠損症、成人成長ホルモン欠損症、肺動脈高血圧症、糖尿病および眼科の治療のために、独自の「TransCon技術」を用いて、既存の薬物のバ―ジョンを改善した製品候補を生成する。   
本社所在地 Tuborg Boulevard 5 Hellerup DK-2900 DNK
代表者氏名 Michael Wolff Jensen マイケル・ウォルフ・イェンセン
代表者役職名 Chairman of the Board Senior Vice President General Counsel
電話番号
設立年月日 2006年
市場名 NASDAQ National Market System
ipoyear 2015年
従業員数 137人
url www.ascendispharma.com
nasdaq_url https://www.nasdaq.com/symbol/asnd
adr_tso 39488792
EBITDA EBITDA(百万ドル) -164.46230
終値(lastsale) 66.33
時価総額(marketcap) 2619291573.36
時価総額 時価総額(百万ドル) 2731.168
売上高 売上高(百万ドル) 0.87316
企業価値(EV) 企業価値(EV)(百万ドル) 2326.0657
当期純利益 当期純利益(百万ドル) -151.88880
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Ascendis Pharma A/S revenues decreased 94% to EUR46K. Net loss increased 15% to EUR64.2M. Revenues reflect Revenue from the rendering of services decrease of 90% to EUR46K. Higher net loss reflects Research and development costs - Balance increase from EUR20.8M to EUR66.4M (expense) Stock-based Compensation in General increase from EUR1.2M to EUR4.6M (expense).

 ASNDのテクニカル分析


 ASNDのニュース

   JPMorgan says stocks are primed for sustained gains in a way they haven't been in years — and identifies 43 names to buy for above-average earnings growth in 2021  2020/12/17 13:15:00 Business Insider
Summary List Placement Despite the economic carnage caused by the worldwide COVID-19 outbreak, US stock indices have soared to all-time highs. That's mostly thanks to mega-cap tech firms, which have seen astonishing appreciation as work, school, and shopping have moved largely online. Now that vaccine rollouts have begun, the stay-at-home environment that boosted these growth stocks will start to change. Still, JPMorgan equity strategists — and their peers at other firms — expect the broader market to rise in 2021. The bank anticipates an up to 19% rally in the S&P 500 that's led mostly by cyclical and value stocks. But this doesn't mean stocks with rapid earnings growth will all suffer; for one, there are many whose valuations haven't skyrocketed like the tech firms at the top of the market. If the path ahead for the economic recovery becomes clearer, some growth stocks — in addition to recovery plays — will see the momentum needed to fuel their path upward. "The equity market is facing one of the best backdrops for sustained gains in years," Dubravko Lakos-Bujas, JPMorgan's chief US equity strategist, said in a recent note. "After a prolonged period of elevated risks (global trade war, COVID-19 pandemic, US election uncertainty, etc.), the outlook is significantly clearing up, especially with news of a highly effective COVID-19 vaccine. "Corporate earnings and labor market recovery continue to come in ahead of expectations," Dubravko continued.
   Ascendis Pharma A/S Announces Planned Board Transition  2020/12/14 21:05:00 GlobeNewswire
– Chair and board member Michael Wolf Jensen will not stand for re-election at 2021 Annual General Meeting – – Board of Directors intends to appoint…
   Ascendis Pharma EPS misses by €0.50, misses on revenue (NASDAQ:ASND)  2020/08/27 20:13:33 Seeking Alpha
Ascendis Pharma (NASDAQ:ASND): Q2 GAAP EPS of -€1.97 misses by €0.50. Revenue of €1.44B (-55.1% Y/Y) misses by $720M. Cash equivalents and marketable secur
   Ascendis Pharma TransCon CNP an Orphan Drug in Europe for dwarfism (NASDAQ:ASND)  2020/08/12 18:53:35 Seeking Alpha
The European Commission has designated Orphan Drug status to Ascendis Pharma's (ASND +0.5%) TransCon C-Type Natriuretic Peptide (CNP) for achondroplasia, a
   Global Hypoparathyroidism Pipeline Monitor 2020 with Analysis of 11 Companies Including Ascendis Pharma, Eli Lilly & Co and Takeda Pharma - ResearchAndMarkets.com  2020/08/03 10:50:00 Business Wire
DUBLIN--(BUSINESS WIRE)--The "Hypoparathyroidism Pipeline Research Monitor, 2020 - Drugs, Companies, Clinical Trials, R&D Pipeline Updates, Status and Outlook" report has been added to ResearchAndMarkets.com's offering. PIPELINE HIGHLIGHTS Hypoparathyroidism is one of the widely researched conditions during 2020 with 11 companies actively focusing on realizing pipeline's potential. Development of Hypoparathyroidism medicines is identified as integral to the strategy of the majority of compa
   Ascendis Pharma EPS misses by €0.50, misses on revenue (NASDAQ:ASND)  2020/08/27 20:13:33 Seeking Alpha
Ascendis Pharma (NASDAQ:ASND): Q2 GAAP EPS of -€1.97 misses by €0.50. Revenue of €1.44B (-55.1% Y/Y) misses by $720M. Cash equivalents and marketable secur
   Ascendis Pharma TransCon CNP an Orphan Drug in Europe for dwarfism (NASDAQ:ASND)  2020/08/12 18:53:35 Seeking Alpha
The European Commission has designated Orphan Drug status to Ascendis Pharma's (ASND +0.5%) TransCon C-Type Natriuretic Peptide (CNP) for achondroplasia, a
   Global Hypoparathyroidism Pipeline Monitor 2020 with Analysis of 11 Companies Including Ascendis Pharma, Eli Lilly & Co and Takeda Pharma - ResearchAndMarkets.com  2020/08/03 10:50:00 Business Wire
DUBLIN--(BUSINESS WIRE)--The "Hypoparathyroidism Pipeline Research Monitor, 2020 - Drugs, Companies, Clinical Trials, R&D Pipeline Updates, Status and Outlook" report has been added to ResearchAndMarkets.com's offering. PIPELINE HIGHLIGHTS Hypoparathyroidism is one of the widely researched conditions during 2020 with 11 companies actively focusing on realizing pipeline's potential. Development of Hypoparathyroidism medicines is identified as integral to the strategy of the majority of compa
   Ascendis Pharma prices ADS offering at $142 (NASDAQ:ASND)  2020/07/08 08:31:26 Seeking Alpha
Ascendis Pharma (NASDAQ:ASND) has priced its public offering of 4,225,352 American Depositary Shares (ADSs), each of which represents one ordinary share, a
   Ascendis Pharma initiates ADSs public offering (NASDAQ:ASND)  2020/07/06 17:08:50 Seeking Alpha
Ascendis Pharma (ASND +1.5%) commenced an underwritten public offering of $500M American Depositary Shares with 30-day underwriters option to purchase up t
   Ascendis Pharma EPS misses by €0.50, misses on revenue (NASDAQ:ASND)  2020/08/27 20:13:33 Seeking Alpha
Ascendis Pharma (NASDAQ:ASND): Q2 GAAP EPS of -€1.97 misses by €0.50. Revenue of €1.44B (-55.1% Y/Y) misses by $720M. Cash equivalents and marketable secur
   Ascendis Pharma TransCon CNP an Orphan Drug in Europe for dwarfism (NASDAQ:ASND)  2020/08/12 18:53:35 Seeking Alpha
The European Commission has designated Orphan Drug status to Ascendis Pharma's (ASND +0.5%) TransCon C-Type Natriuretic Peptide (CNP) for achondroplasia, a
   Global Hypoparathyroidism Pipeline Monitor 2020 with Analysis of 11 Companies Including Ascendis Pharma, Eli Lilly & Co and Takeda Pharma - ResearchAndMarkets.com  2020/08/03 10:50:00 Business Wire
DUBLIN--(BUSINESS WIRE)--The "Hypoparathyroidism Pipeline Research Monitor, 2020 - Drugs, Companies, Clinical Trials, R&D Pipeline Updates, Status and Outlook" report has been added to ResearchAndMarkets.com's offering. PIPELINE HIGHLIGHTS Hypoparathyroidism is one of the widely researched conditions during 2020 with 11 companies actively focusing on realizing pipeline's potential. Development of Hypoparathyroidism medicines is identified as integral to the strategy of the majority of compa
   Ascendis Pharma prices ADS offering at $142 (NASDAQ:ASND)  2020/07/08 08:31:26 Seeking Alpha
Ascendis Pharma (NASDAQ:ASND) has priced its public offering of 4,225,352 American Depositary Shares (ADSs), each of which represents one ordinary share, a
   Ascendis Pharma initiates ADSs public offering (NASDAQ:ASND)  2020/07/06 17:08:50 Seeking Alpha
Ascendis Pharma (ASND +1.5%) commenced an underwritten public offering of $500M American Depositary Shares with 30-day underwriters option to purchase up t

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 アセンディス・ファ―マ ASND Ascendis Pharma A/S)

 twitter  (公式ツイッターやCEOツイッターなど)